Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis.
Sep 10, 2015 at 3:00 PM ET
Rodman & Renshaw 17th Annual Global Investment Conference
Oct 20, 2015
2015 BIO Investor Forum